GlassScriptPhysician profile
Kaitlin Noelle Erickson
NPI 1821641671
$1,288.69
in general payments reported to CMS, 2019-2025
15 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.00 · 2022: $173 · 2023: $229 · 2024: $300 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $162.37 | 2024 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $147.84 | 2021-2024 | Ultomiris, Soliris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.71 | 2021-2025 | Xifaxan |
| Abbvie INC. | $123.93 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $120.98 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $106.84 | 2021-2022 | |
| Leo Pharma INC. | $105.35 | 2025 | Adbry |
| Janssen Pharmaceuticals, INC | $104.90 | 2023-2024 | Xarelto |
| Sun Pharmaceutical Industries INC. | $91.64 | 2025 | |
| Novartis Pharmaceuticals Corporation | $71.39 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $32.29 | 2021-2022 | |
| Pfizer INC. | $22.78 | 2022 | |
| Csl Behring | $22.45 | 2022 | |
| Genzyme Corporation | $19.07 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.15 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.